Rubicon Research Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 12 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹26.0K Cr
Strong growth trajectory continues with broad-based demand across the product portfolio. Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY.
From Rubicon Research Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,725
Market Cap
₹26.0K Cr
P/E Ratio
105.5
How does Rubicon Research Ltd rank in Pharmaceuticals & Biotechnology?
Compare Rubicon Research Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Rubicon Research Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net profit ₹73 Cr.
Full financials →📊 Revenue & Sales Performance
- →Strong growth trajectory continues with broad-based demand across the product portfolio.
- →Revenue for Q4 FY26 showed a 44% year-on-year growth, with sequential growth of around 8%.
- →The company expects sustained demand and increased outsourcing for at least the next couple of quarters.
- →Upcoming 24 product filings under US FDA review indicate a robust pipeline, with launches expected over the next 12 to 18 months.
- →Pithampur facility ramp-up anticipated within 12 to 18 months post FDA inspection, enhancing internal manufacturing capacity.
- →Capex of around INR 300 crores planned over the next two years to support growth and capacity expansion.
- →The company aims to maintain EBITDA margins at 22-23% while expanding sales.
- →Confident in beating overall industry growth (IPM growth) by fiscal 2028.
📈 Profitability & Margins
- →Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY.
- →For FY26, revenue grew 37%, EBITDA 52%, and PAT 84%, indicating healthy profitability trends.
- →Management expects sustained revenue growth ahead driven by broad-based demand and new product launches (24 products under US FDA review).
- →EBITDA margin guidance is maintained at 22%-23%, considering ongoing expenses (ESOP, Arinna acquisition, Pithampur costs) and potential raw material/logistics cost volatility.
- →R&D productivity stands at 5.9x with continued focus on specialty and drug-device combination portfolio, underpinning quality growth.
- →Capex of around INR 300 crores is planned over the next two years to support capacity expansion, especially the ramp-up of Pithampur site expected within 12-18 months.
- →Despite recent increases, finance costs may not decrease soon due to partial debt funding of acquisitions.
- →Overall, the company targets sustained profitable growth with stable margins and expanding pipeline.
🏗️ Capital Expenditure Plans
- →Capex guidance for the next two years is projected to be close to INR 300 crores across various sites (Page 14).
- →The Pithampur facility will be ramped up in the coming year to meet the strong demand (Page 14).
- →Capex philosophy: capex will lag sustained demand; capex incurred only after proven long-term demand to avoid overcapacity (Page 14).
- →Recent capex includes acquisition of the Pithampur facility and additional investments (Page 4).
- →Part of cash outflow in investing activities includes capex of INR 800 million along with acquisition and other inorganic outflows (Page 4).
- →The company is keeping a "war chest" for any interesting inorganic acquisition opportunities, aligned with their RHP strategy, indicating potential future strategic investments (Page 17).
💰 Fundraising & Capital Structure
- →Rubicon Research Limited raised around INR 161 crores through IPO, with approximately INR 100 crores still unutilized as of May 2026.
- →The unutilized IPO funds are partly planned for use in the Arena acquisition.
- →Additionally, the Arena acquisition has been partly funded through debt of around INR 75 crores.
- →The company is maintaining a "war chest" for any attractive inorganic acquisition opportunities as stated in their RHP strategy.
- →No specific new acquisitions or fundraising plans (debt or equity) for FY 2027 have been disclosed; management will announce when there is certainty about any future transactions.
- →Finance costs are currently elevated due to remaining debt repayments and financing of factoring receivables, as well as debt used for recent acquisitions.
- →Finance cost may not reduce immediately due to recent acquisition-related debt.
📋 Order Book & Pipeline
- →Rubicon Research has a strong revenue visibility with broad-based demand across its portfolio.
- →There are 24 products currently under review with the US FDA, indicating a robust pending approval pipeline.
- →These 24 products under FDA review are expected to launch over the next 12 to 18 months, contributing to growth.
- →Inventory levels have increased as part of preparation for upcoming product launches.
- →The company is ramping up capacity, especially at its Pithampur facility, expected to reach decent utilization within 12 to 18 months post-FDA inspection.
- →Demand is expected to be sustained and growing, necessitating outsourced manufacturing until internal capex expansions are fully operational.
Key Metrics
Frequently Asked Questions
What were Rubicon Research Ltd Q4 FY26 results?
Strong growth trajectory continues with broad-based demand across the product portfolio. Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY.
What is Rubicon Research Ltd share price analysis?
Rubicon Research Ltd currently shows a neutral. The stock trades at a P/E of 105.5 with a market cap of ₹26,041 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research Ltd planning capital expenditure?
Capex guidance for the next two years is projected to be close to INR 300 crores across various sites (Page 14).
Keep Rubicon Research Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.